How to Get Crestor (Rosuvastatin) in Delaware

Who Can Prescribe Crestor in Delaware?

Any clinician holding an active Delaware prescribing license can write a rosuvastatin prescription. This includes physicians (MD/DO), nurse practitioners (NP), and physician assistants (PA). Delaware grants NPs full practice authority, meaning they can evaluate, diagnose, and prescribe independently without a collaborative agreement.

MDs and DOs

Board-certified internists, family medicine physicians, and cardiologists are the most common prescribers. If your LDL cholesterol exceeds 190 mg/dL or you carry a 10-year ASCVD risk above 7.5%, the 2018 AHA/ACC Cholesterol Guideline recommends moderate- to high-intensity statin therapy. Rosuvastatin 20 to 40 mg daily qualifies as high-intensity [2].

Nurse Practitioners and Physician Assistants

Delaware NPs practice under full authority per Title 24, Chapter 19 of the Delaware Code. PAs require a collaboration agreement but can prescribe Schedule II through V medications and non-controlled drugs like rosuvastatin without restriction. Both provider types routinely manage dyslipidemia in primary care, urgent care, and telehealth settings.

Specialists vs. Primary Care

Most rosuvastatin prescriptions originate in primary care. Referral to a lipid specialist or cardiologist is typically reserved for patients with familial hypercholesterolemia, statin intolerance affecting two or more agents, or LDL that remains above goal on maximally tolerated therapy.

Telehealth Access to Rosuvastatin in Delaware

Delaware permits telehealth prescribing of rosuvastatin with no in-person visit requirement. The state's telehealth parity law (HB 348, signed 2020) requires commercial insurers to cover telehealth services at the same rate as in-person visits, and Delaware Medicaid extends the same coverage [3].

How a Telehealth Visit Works

A typical visit lasts 10 to 20 minutes. The clinician reviews your lipid panel, cardiovascular history, and current medications. If rosuvastatin is appropriate, the prescription is sent electronically to a Delaware pharmacy or a mail-order pharmacy licensed in the state. Most platforms deliver prescriptions within 24 to 48 hours of the consultation.

What You Need Before the Visit

Bring a fasting lipid panel drawn within the past 12 months. The panel should include total cholesterol, LDL-C, HDL-C, and triglycerides. A hepatic function panel (ALT, AST) is also recommended before starting statin therapy, per FDA labeling [4]. If you do not have recent labs, many telehealth platforms will order them at a local Delaware draw site (Quest, Labcorp, or hospital-affiliated labs).

Choosing a Telehealth Platform

Look for platforms that employ Delaware-licensed clinicians, send prescriptions to your preferred Delaware pharmacy, and accept your insurance. HealthRX connects Delaware residents with licensed providers who can evaluate your cardiovascular risk and prescribe rosuvastatin during a single visit if clinically appropriate.

Labs Required Before and During Rosuvastatin Therapy

Rosuvastatin is processed primarily by the liver, and baseline lab work helps identify patients who need dose adjustments or closer monitoring. The Crestor prescribing information recommends specific assessments before and after initiation [4].

Pre-Prescription Labs

A fasting lipid panel establishes your baseline LDL-C, HDL-C, total cholesterol, and triglycerides. A hepatic function panel (ALT, AST) screens for pre-existing liver disease. Creatine kinase (CK) testing is not routine but should be drawn in patients reporting baseline muscle pain, those with hypothyroidism, or those with renal impairment.

Follow-Up Monitoring

Repeat the fasting lipid panel 4 to 12 weeks after starting therapy or adjusting the dose to confirm LDL-C response. The 2018 AHA/ACC guideline recommends checking liver enzymes if symptoms of hepatotoxicity develop (fatigue, anorexia, dark urine) but no longer mandates routine periodic ALT/AST monitoring for all statin users [2]. For rosuvastatin specifically, Asian-American patients should start at 5 mg due to a roughly twofold increase in systemic exposure, per pharmacokinetic data in the FDA label [4].

eGFR Considerations

Rosuvastatin 40 mg is contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m². Patients with eGFR 30 to 60 should not exceed 10 mg daily unless closely monitored. A basic metabolic panel or cystatin C-based eGFR drawn within the past year satisfies this screening requirement.

Delaware Pharmacy Options for Rosuvastatin

Generic rosuvastatin is stocked at virtually every retail pharmacy in Delaware. The state's three counties (New Castle, Kent, Sussex) each have multiple chains and independent pharmacies dispensing the drug.

Retail Chains

CVS, Walgreens, Rite Aid, and Walmart pharmacies in Wilmington, Dover, Newark, and across Sussex County carry generic rosuvastatin in 5 mg, 10 mg, 20 mg, and 40 mg tablets. Cash prices for a 30-day supply of generic rosuvastatin 10 mg typically range from $4 at discount programs to $15 without a discount card.

Mail-Order and 503A Compounding

Delaware-licensed 503A pharmacies may compound rosuvastatin in custom dosage forms for patients with specific needs (e.g., dye-free capsules or liquid suspensions for patients with swallowing difficulty). These pharmacies can ship directly to Delaware addresses. Mail-order pharmacies (Express Scripts, CVS Caremark, OptumRx) also deliver to Delaware and often offer 90-day supplies at lower per-unit cost.

Specialty vs. Standard Dispensing

Rosuvastatin does not require specialty pharmacy dispensing. It is a standard oral generic that any licensed pharmacy can dispense without special storage, REMS enrollment, or restricted distribution.

Insurance and Cost in Delaware

The cost of rosuvastatin depends on your insurance plan, the specific dose, and whether you use brand-name Crestor or the generic. Brand Crestor carries a wholesale acquisition cost of roughly $290 per month, while generic rosuvastatin can be as low as $4 with a discount program.

Delaware Medicaid

Delaware Medicaid, administered through the Diamond State Health Plan, covers generic rosuvastatin for the treatment of hyperlipidemia and ASCVD prevention. Prior authorization is required. The PA process verifies diagnosis, confirms that the patient has tried or has a contraindication to preferred formulary statins, and documents the prescribing clinician's rationale.

Commercial Insurance

Most Delaware commercial plans (Highmark BCBS Delaware, Aetna, Cigna, UnitedHealthcare) place generic rosuvastatin on Tier 1 or Tier 2, with copays between $0 and $15. Brand-name Crestor is typically Tier 3 or non-preferred, requiring a higher copay or prior authorization demonstrating generic intolerance.

Uninsured Patients

A 2023 analysis of GoodRx, RxSaver, and Cost Plus Drugs pricing found generic rosuvastatin 10 mg available for under $5 per month in the Wilmington metro area [5]. AstraZeneca no longer offers a branded Crestor patient assistance program for most patients since generic entry, but NeedyMeds and state-level programs may provide additional savings.

Prior Authorization Requirements in Delaware

Prior authorization (PA) is a payer-level requirement, not a state-level one. Delaware Medicaid and some commercial plans require PA for rosuvastatin under specific circumstances.

When PA Is Triggered

Delaware Medicaid triggers PA when a prescriber requests brand Crestor instead of generic rosuvastatin, when the requested dose exceeds 20 mg, or when the patient has not yet tried a preferred statin (typically atorvastatin or simvastatin). Commercial plans vary, but the most common PA trigger is a request for brand over generic.

Documentation Needed

The prescriber must submit the PA form (often electronic through CoverMyMeds or SureScripts) with the following: confirmed ICD-10 diagnosis (E78.0 for pure hypercholesterolemia, E78.5 for unspecified dyslipidemia, or I25.10 for ASCVD), recent lipid panel results, a list of previously tried statins with dates and outcomes, and a clinical rationale for the requested drug and dose.

Timeline

Delaware Medicaid must respond to standard PA requests within 24 hours and urgent requests within 4 hours. During the PA review period, the patient is entitled to a 72-hour emergency supply if the medication is medically necessary and delay could cause harm. Commercial plan timelines vary but typically fall within 48 to 72 hours.

Clinical Evidence Supporting Rosuvastatin

Rosuvastatin has one of the strongest evidence bases of any statin. Two trials in particular anchor its use in primary and secondary ASCVD prevention.

JUPITER Trial

The JUPITER trial (N=17,802) randomized adults with LDL-C below 130 mg/dL and high-sensitivity C-reactive protein (hsCRP) of 2.0 mg/L or higher to rosuvastatin 20 mg or placebo [1]. At a median follow-up of 1.9 years, rosuvastatin reduced the primary composite endpoint (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death) by 44% (HR 0.56; 95% CI, 0.46 to 0.69; P<0.00001). LDL-C dropped 50% from baseline. The trial was stopped early because of clear benefit.

METEOR Trial

The METEOR trial (N=984) studied rosuvastatin 40 mg versus placebo in patients with subclinical atherosclerosis measured by carotid intima-media thickness (CIMT) [6]. Over 2 years, rosuvastatin slowed the rate of CIMT progression compared to placebo (p<0.001). This trial supported rosuvastatin's role in early intervention for patients with measurable but asymptomatic vascular disease.

AHA/ACC Guideline Positioning

The 2018 AHA/ACC Cholesterol Guideline classifies rosuvastatin 20 to 40 mg as high-intensity statin therapy, expected to reduce LDL-C by 50% or more [2]. It is one of only two statins (alongside atorvastatin 40 to 80 mg) that qualifies for the high-intensity category. For patients aged 40 to 75 with diabetes mellitus, the guideline recommends at least moderate-intensity therapy, with high-intensity preferred when the 10-year ASCVD risk exceeds 20%.

Transferring a Crestor Prescription to Delaware

If you are moving to Delaware or visiting and need to continue rosuvastatin therapy, Delaware law permits prescription transfers between pharmacies within the state and across state lines.

In-State Transfers

Call your new Delaware pharmacy with the name and phone number of your current pharmacy. The receiving pharmacist contacts the transferring pharmacy directly. Transfers of non-controlled medications like rosuvastatin are unlimited in frequency.

Out-of-State Transfers

Delaware accepts prescription transfers from all 50 states for non-controlled medications. The process is identical: provide your new Delaware pharmacy with your current pharmacy's information. Electronic transfers through SureScripts are the fastest method. If your out-of-state prescription has no remaining refills, your Delaware pharmacist can contact the prescriber for a new authorization, or you can schedule a telehealth visit with a Delaware-licensed provider.

Military and VA Prescriptions

TRICARE and VA prescriptions can be filled at any TRICARE-network or VA-contracted pharmacy in Delaware. The Wilmington VA Medical Center pharmacy dispenses rosuvastatin directly to enrolled veterans.

Side Effects and Safety Monitoring

Rosuvastatin is well-tolerated at FDA-approved doses, but patients should be aware of the most commonly reported adverse effects and the rare but serious risks.

Common Side Effects

In clinical trials, the most frequent adverse reactions at the 10 mg to 20 mg dose included headache (5.5%), myalgia (3.1%), abdominal pain (2.2%), and nausea (2.1%), per the FDA label [4]. These rates were similar to placebo in JUPITER [1].

Myopathy and Rhabdomyolysis

Statin-associated muscle symptoms (SAMS) affect approximately 5% to 10% of statin users in observational studies, though the SAMSON trial (N=60) found that roughly 90% of muscle symptoms attributed to statins also occurred on placebo, suggesting a large nocebo contribution [7]. True rhabdomyolysis is rare, occurring at a rate of approximately 1 per 100,000 patient-years. Risk increases with the 40 mg dose, concomitant use of cyclosporine, gemfibrozil, or certain protease inhibitors, and in patients of Asian descent.

Hepatic and Renal Monitoring

Liver enzyme elevations above three times the upper limit of normal occurred in 0.2% of rosuvastatin-treated patients in pre-approval trials [4]. Proteinuria has been reported at the 40 mg dose; the FDA label recommends dose reduction if unexplained persistent proteinuria develops during routine urinalysis.

Delaware-Specific Regulatory Notes

Delaware does not impose additional state-level restrictions on rosuvastatin prescribing beyond standard DEA and Board of Pharmacy requirements.

Prescribing Authority

The Delaware Board of Medical Licensure and Discipline governs MD/DO prescribing. The Delaware Board of Nursing regulates APRN (NP) prescribing. PAs are regulated under the PA Advisory Council. All three boards recognize rosuvastatin as a non-controlled medication that does not require a separate controlled-substance registration.

Telehealth Regulations

Delaware's telehealth statute does not require an initial in-person visit before a telehealth prescription. Providers must hold a Delaware license or a multistate compact license that includes Delaware. The Interstate Medical Licensure Compact, of which Delaware is a member, expedites physician licensing across participating states.

Pharmacy Compounding

Delaware follows FDA guidance on 503A compounding. A 503A pharmacy located in Delaware can compound rosuvastatin for an individual patient based on a valid prescription. Out-of-state 503A pharmacies shipping to Delaware must be licensed by the Delaware Board of Pharmacy as a non-resident pharmacy.

Patients starting rosuvastatin should have a repeat fasting lipid panel drawn 6 to 12 weeks after initiation to confirm at least a 50% LDL-C reduction on high-intensity dosing or a 30% to 49% reduction on moderate-intensity dosing, per the 2018 AHA/ACC threshold-based monitoring recommendation [2].